MDMX is essential for the regulation of p53 protein levels in the absence of a functional MDM2 C-terminal tail

Jack D. Sanford1,2,3, Jing Yang1,2,4, Jing Han1,2,4, Laura A. Tollini1,2,3, Aiwen Jin1,2 and Yanping Zhang1,2,3,5*

Abstract

Background: MDM2 is an E3 ubiquitin ligase that is able to ubiquitinate p53, targeting it for proteasomal degradation. Its homologue MDMX does not have innate E3 activity, but is able to dimerize with MDM2. Although mouse models have demonstrated both MDM2 and MDMX are individually essential for p53 regulation, the significance of MDM2-MDMX heterodimerization is only partially understood and sometimes controversial. MDM2C462A mice, where the C462A mutation abolishes MDM2 E3 ligase activity as well as its ability to dimerize with MDMX, die during embryogenesis. In contrast, the MDM2Y487A mice, where the Y487A mutation at MDM2 C-terminus significantly reduces its E3 ligase activity without disrupting MDM2-MDMX binding, survive normally even though p53 is expressed to high levels. This indicates that the MDM2-MDMX heterodimerization plays a critical role in the regulation of p53. However, it remains unclear whether MDMX is essential for the regulation of p53 protein levels in the context of an endogenous MDM2 C-terminal tail mutation.

Results: Here, we studied the significance of MDM2-MDMX binding in an MDM2 E3 ligase deficient context using the MDM2Y487A mouse embryonic fibroblast (MEF) cells. Surprisingly, down-regulation of MDMX in MDM2 Y487A MEFs resulted in a significant increase of p53 protein levels. Conversely, ectopic overexpression of MDMX reduced p53 protein levels in MDM2 Y487A MEFs. Mutations of the RING domain of MDMX prevented MDMX-MDM2 binding, and ablated MDMX-mediated suppression of p53 protein expression. Additionally, DNA damage treatment and nuclear sequestration of MDMX inhibited MDMX activity to suppress p53 protein expression.

Conclusions: These results suggest that MDMX plays a key role in suppressing p53 protein expression in the absence of normal MDM2 E3 ligase activity. We found that the ability of MDMX to suppress p53 levels requires MDM2 binding and its cytoplasmic localization, and this ability is abrogated by DNA damage. Hence, MDMX is essential for the regulation of p53 protein levels in the context of an MDM2 C-terminal mutation that disrupts its E3 ligase activity but not MDMX binding. Our study is the first to examine the role of MDMX in the regulation of p53 in the context of endogenous MDM2 C-terminal mutant MEF cells.

Keywords: P53, MDM2, MDMX, Cancer, Protein degradation
Background
p53 is a critical tumor suppressor that is frequently mutated in human cancers [1]. p53 can suppress tumorigenesis through multiple mechanisms, including induction of cell cycle arrest and apoptosis, regulation of the DNA damage response, and regulation of cellular metabolism [1]. p53 function can also be lost through overexpression or genetic amplification of endogenous suppressors of p53, chiefly MDM2 and MDMX. Deletion of either MDM2 or MDMX in mice results in unregulated p53 activity that leads to early embryonic lethality [2–4]. Although it is clear that MDM2 and MDMX antagonize p53 function, the mechanism of action of these proteins remains only partially understood.

MDM2 is a RING-type E3 ubiquitin ligase that is able to ubiquitinate p53, targeting it for proteosomal degradation [5–7]. MDM2 is also able to inhibit p53 transcriptional activity by binding to the N-terminal transcriptional activating domain (TAD) of p53 [8]. Although MDMX also has a RING domain, biochemical studies have shown that MDMX lacks innate E3 ligase activity [9]. Similar to MDM2, MDMX has been shown to bind p53 and inhibit its transcriptional activity [10]. MDM2 and MDMX can interact with each other through their respective RING domains [11]. Recent structural studies have shown that MDM2 dimerization is required for its E3 ligase activity [12, 13]. MDM2 is able to form both MDM2-MDM2 homodimers, as well as MDM2-MDMX heterodimers [13–16]. However, the consequences MDM2-MDMX heterodimerization remain unclear. One major point of confusion lies in conflicting in vitro data. For example, studies have shown that MDMX is able to either inhibit MDM2 E3 ligase activity [9] or promote MDM2 E3 ligase activity [17].

In order to elucidate the role of MDM2-MDMX dimerization in the regulation of p53 under physiological conditions, we generated MDM2 C462A and MDM2 Y487A mutant mice. The MDM2 C462A mutation disrupts MDM2 RING function, preventing MDM2-MDMX heterodimer formation and inhibiting MDM2 E3 ligase activity. The MDM2 C462A mouse embryos are not viable, indicating that proper structure of the MDM2 RING domain is essential for the regulation of p53 during early embryonic development [18]. The MDM2 Y487A mutation, on the other hand, ablates MDM2 E3 ligase activity without interrupting MDM2-MDMX heterodimer formation [19–21], allowing for separate analysis of the relative importance of heterodimerization and E3 ligase activity. Surprisingly, the MDM2 Y487A mice were viable and developmentally normal despite expressing high levels of p53, but the mice were hypersensitive to DNA damage. These results suggest that the MDM2-MDMX heterodimerization is critical for suppressing p53 activity for normal development, while MDM2 E3 ligase activity is indispensable for recovery from DNA damage [21]. However, it remains unclear whether MDMX is essential for the regulation of p53 protein levels in the context of an endogenous MDM2 C-terminal tail mutation that disrupts MDM2 E3 ligase function but not MDM2-MDMX heterodimerization. In this paper, we address this knowledge gap by examining the role of MDMX in the regulation of p53 in the context of endogenous MDM2 Y487A. We find that MDMX is essential for the regulation of p53 protein levels in MDM2 Y487A MEFs, even in the absence of detectable MDM2 E3 ligase activity. Furthermore, we find that this activity is localized to the cytoplasm and is ablated by DNA damage.

Results
Down-regulation of MDMX in MDM2 Y487A MEFs increases p53 protein levels
As previously shown, the MDM2 Y487A mutation greatly inhibits the E3 ligase activity of MDM2 [19–21]. Mouse embryonic fibroblast (MEF) cells generated from MDM2 Y487A/Y487A mice (MDM2 Y487A/Y487A hereafter) display higher p53 protein levels than WT MDM2 MEFs (Fig. 1A). This occurs even though MDM2 Y487A/Y487A MEFs have higher levels of endogenous MDM2 compared to WT MEFs. We wondered whether MDMX plays any role in the regulation of p53 protein levels in the MDM2 Y487A/Y487A MEFs. In order to test this, we knocked down MDMX using siRNA in WT and MDM2 Y487A/Y487A MEFs and examined p53 protein levels. Knockdown of MDMX resulted in an increase in p53 protein levels in WT MEFs, indicating MDMX negatively regulates p53 protein levels in the context of WT MDM2 (Fig. 1B, left). Surprisingly, knockdown of MDMX in MDM2 Y487A/Y487A MEFs resulted in an even greater increase in p53 protein levels than was observed in the WT MEFs (Fig. 1B, right). While knockdown of MDMX in WT MEFs resulted in about a two-fold increase in p53 levels, knockdown of MDMX in MDM2 Y487A/Y487A MEFs resulted in more than a five-fold increase in p53 levels (Fig. 1B). To validate the siRNA knockdown results, we utilized lentiviral-guided shRNA targeting MDMX. Consistent with the siRNA results, shRNA-mediated MDMX knockdown resulted in moderate increase in p53 levels in WT MEFs and more pronounced increases in p53 levels in MDM2 Y487A/Y487A MEFs (Fig. 1C). Importantly, the degree of p53 protein increase in MDM2 Y487A/Y487A MEFs inversely correlated with the degree of MDMX knockdown, indicating a causal relationship. These results show that despite the increased stability of p53 in the MDM2 Y487A/Y487A MEFs, p53 protein levels can be further increased by MDMX knockdown, suggesting that MDMX suppresses p53 protein expression in the absence of detectable MDM2 E3 activity.
Overexpression of MDMX in MDM2\textsuperscript{487/487} MEFs decreases p53 protein levels

To further validate the above observation of MDMX suppressing p53 protein expression, we utilized a lentiviral system to overexpress MDMX in the MEF cell system. In order to more accurately investigate the relationship between MDMX protein levels and p53 protein levels, we first performed a titration experiment in which increasing doses of MDMX lentivirus were added to MDM2\textsuperscript{487/487} MEF cells. Increasing MDMX overexpression resulted in a dose-dependent decrease in p53 protein levels, suggesting a causal relationship (Fig. 2A). Continued increase of MDMX overexpression did not result in complete eliminating p53 protein levels, suggesting a causal relationship (Fig. 2A). Continued increase of MDMX overexpression did not result in complete eliminating p53 protein expression, suggesting that MDMX is not the only rate-limiting factor for the regulation of p53 protein levels in this system (Fig. 2A, lanes 4–6). Previous studies have shown that MDMX overexpression is able to reactivate the E3 ligase activity of MDM2\textsuperscript{Y489A} mutant [19, 20]. Therefore, we hypothesized that the endogenous MDM2\textsuperscript{Y487A} is a rate-limiting factor and MDMX overexpression reactivates MDM2\textsuperscript{Y487A} E3 ligase activity. To test this hypothesis, we investigated whether MDMX-mediated suppression of p53 expression was dependent on its ability to bind MDM2. We first generated a number of MDMX deletion mutants (Fig. 2B), and assessed their MDM2-binding activity. Consistent with previous studies showing MDM2 and MDMX interact through their respective RING domains [11–13], deletion of MDMX RING domain (MDMX\textsuperscript{ΔRING}), but not other regions of MDMX, prevented MDM2-MDMX binding (Fig. 2C). We then tested the ability of these MDMX deletion mutants to suppress p53 using MDMX\textsuperscript{ΔAD}, which maintains MDM2 binding, and MDMX\textsuperscript{ΔRING}, which does not bind MDM2. Overexpression of full-length MDMX and MDMX\textsuperscript{ΔAD} was able to suppress p53 protein levels to a similar degree, while overexpression of MDMX\textsuperscript{ΔRING} was unable to inhibit p53 protein expression (Fig. 2D), indicating that MDM2-MDMX binding is necessary for MDMX to suppress p53 expression in MDM2\textsuperscript{487/487} MEFs. Together, these data show that down-regulation of MDMX increases p53 levels while overexpression of MDMX decreases p53 levels in the E3 defective MDM2\textsuperscript{487/487}.
MEFs, and the ability of MDMX to regulate p53 levels depends on MDM2 binding.

**DNA damage inhibits MDMX suppression of p53 protein expression**

Studies have shown that DNA damage increases p53 protein stability and activity through a variety of mechanisms. DNA damage promotes p53 phosphorylation that decreases the affinity of MDM2 and MDMX for p53 [22]. DNA damage also promotes phosphorylation of MDM2 and MDMX in a manner that decreases their ability to inhibit p53 [23–25]. In order to determine whether DNA damage affects the ability of MDMX to suppress p53 protein expression in the MDM2 487/487 context, MDM2 487/487 MEF cells were infected with empty lentivirus vector (EV) or MDMX lentivirus. The MEFs were then left untreated, or treated with 1 μg/mL doxorubicin or 10 Gy ionizing irradiation to cause DNA damage. While MDMX strongly inhibited p53 protein expression in untreated MDM2 487/487 MEFs, doxorubicin and ionizing radiation treatment ablated MDMX activity, suggesting that MDMX activity to suppress p53 levels is inhibited by DNA damage treatment in this context (Fig. 3).

The p53-suppressing activity of MDMX is localized to the cytoplasm

DNA damage results in translocation of MDMX from the cytoplasm to the nucleus [26–28]. It has been hypothesized that nuclear translocation of MDMX results in its degradation by MDM2 [24, 27]. Alternatively, it has been proposed that nuclear translocation of MDMX inhibits MDM2 E3 ligase activity, leading to p53 stabilization [9, 29]. In order to determine the effect of nuclear localization of MDMX on its ability to suppress p53 protein levels, we attached an SV40 nuclear localization signal (NLS) sequence to the N-terminus of MDMX to generate the NLS-MDMX lentivirus. We overexpressed NLS-MDMX in MDM2 487/487 MEFs and examined their subcellular localization.
Immunofluorescent staining indicated that WT MDMX localizes predominantly to the cytoplasm, while NLS-MDMX localizes predominantly to the nucleus (Fig. 4A). Interestingly, NLS-MDMX overexpression resulted in a much weaker effect on suppressing p53 protein levels, despite a higher level of NLS-MDMX expression than that of WT MDMX in this experiment (Fig. 4B), suggesting that the activity of MDMX to suppress p53 protein expression is localized to the cytoplasm. Together, our results suggest that MDMX suppresses p53 protein levels in MDM2{487/487} MEFs in an MDM2 binding- and cytoplasmic-localization dependent manner.

Discussion
Recent biochemical studies have shown that the C-terminal tail, downstream of the RING domain, is essential for MDM2 E3 ligase activity, and that mutation of C-terminal amino acids of MDM2, including Y487 (Y489 in human MDM2), ablates MDM2 E3 ligase activity, and that MDMX overexpression can restore the E3 ligase activity of C-terminal mutant MDM2 {13, 16, 19, 20}. These studies suggest that successful polyubiquitination of p53 requires an intact MDM2 C-terminal tail. Our data are consistent with this model. We have shown that in MDM2{487/487} MEFs, MDMX knockdown results in a great increase in p53 protein levels (Fig. 1), despite the fact that p53 protein levels in MDM2{487/487} MEFs were already significantly higher than in their WT MEF counterparts. This suggests that MDM2{487/487} MEFs are more dependent on MDMX for the regulation of p53 protein levels than WT MEFs. One explanation for this observation is that in WT MEFs, MDM2 homodimers are able to regulate p53 protein levels in the absence of MDMX. In MDM2{487/487} MEFs, however, there is no available functional MDM2 C-terminal tail, and therefore MDM2{487/487} homodimers cannot polyubiquitinate p53, increasing reliance on MDMX for the degradation of p53. This model is consistent with a previous study where the RING domain of MDMX was deleted {30}. In the study, p53 degradation was shown to occur at a similar rate in MDMX{ΔRING} MEFs as in MDMX{+/+} MEFs, indicating that in a MEF cell system MDM2 can degrade p53 in the absence of MDM2-MDMX heterodimerization {30}. However, this study uses exogenous p53, as MDMX{ΔRING} MEFs are nonviable with endogenous p53.

In the current study, we showed that MDMX overexpression results in a decrease in p53 protein levels in the context of E3 ligase deficient MDM2{487/487} MEFs. However, in an MDMX overexpression titration experiment,
the maximal effect of MDMX overexpression was reached using a relatively low dose of MDMX lentivirus (Fig. 2A). This suggests that endogenous factors, other than ectopically overexpressed MDMX, play a rate-limiting role for suppression of p53 protein levels. Deletion of the RING domain of MDMX ablates the ability of MDMX to suppress p53 protein levels, suggesting that such a function of MDMX relies on interaction with MDM2 (Fig. 2C). One possible explanation for these data is that MDMX is able to restore MDM2Y487A E3 ligase activity by increasing the ratio of functional MDM2-MDMX heterodimers relative to nonfunctional MDM2Y487A homodimers. Previous studies have shown that supplementation of MDMX to MDM2 C-terminal tail mutations results in reactivation of MDM2 E3 ligase activity [13, 16, 19, 20]. Our study supports this notion in a context of endogenous MDM2Y487A.

The role of MDMX subcellular localization in p53 regulation remains poorly understood and controversial. While p53 and MDM2 are both primarily localized to the nucleus, MDMX is primarily localized to the cytoplasm. Previous studies have shown that DNA damage leads to nuclear import of MDMX [26, 27]. Several hypotheses have emerged to explain the nuclear translocation of MDMX. One such hypothesis is that MDMX nuclear import leads to the degradation of MDMX by MDM2 [27]. It has also been suggested that MDMX can increase p53 stability by inhibiting MDM2 following DNA damage and nuclear translocation [9, 29]. Our data show that nuclear sequestration inhibits the capacity of MDMX to suppress p53 in MDM2Y487A MEFs (Fig. 4). This is consistent with previous studies showing that p53 polyubiquitination and degradation primarily occurs in the cytoplasm, and that blocking p53 nuclear export

![Fig. 4](image_url)
using leptomycin B (LMB) results in decreased p53 polyubiquitination and degradation [31]. Previous studies have shown that nuclear export of p53 is essential for p53 degradation, suggesting that p53 is not normally degraded by nuclear proteasomes [32, 33]. Therefore, if p53 polyubiquitination occurs in the nucleus, as it would in the context of NLS-MDMX nuclear sequestration, polyubiquitinated p53 would have to travel to the cytoplasm prior to being degraded by cytoplasmic proteasomes. This would leave p53 more susceptible to cytoplasmic deubiquitinases, such as USP10, than it would be if both polyubiquitination and proteasomal degradation occurred simultaneously in the cytoplasm [34]. Thus, nuclear import of MDMX could increase p53 stability by increasing the distance between the site of polyubiquitination and the site of degradation. It is also possible that MDM2-MDMX heterodimers have reduced activity in the nucleus, or that nuclear sequestration of MDMX also results in nuclear sequestration of polyubiquitinated p53, inhibiting its degradation. Future studies are required to determine the mechanism through which nuclear sequestration of MDMX inhibits its function.

Conclusions
This study shows that MDMX is essential for the regulation of p53 protein levels in the context of an endogenous C-terminal tail mutant MDM2. Furthermore, MDMX activity in this context relies on MDM2-MDMX binding, is inhibited by DNA damage, and is localized to the cytoplasm. These results have implications for the function of MDM2-MDMX heterodimers and the viability of the MDM2 Y487A/Y487A mutant mouse model.

Experimental procedures
Cell culture and reagents
Mouse embryonic fibroblasts (MEF) were generated from MDM2 Y487A/Y487A and MDM2 +/+ embryos and passage 0 MEF cells were frozen down in liquid nitrogen for future use. MEF cells were cultured in a humidified 37 °C, 5% CO2, 3% O2 incubator. Cells were cultured in Dulbecco’s modified Eagle’s medium (Sigma) supplied with 10% fetal bovine serum (Sigma) and penicillin (100 IU/ml)/streptomycin (Sigma, 100 mg/ml). HEK293 cells were obtained through the ATCC and cultured in a humidified 37 °C, 5% CO2 incubator in Dulbecco’s modified Eagle’s medium (Sigma) supplied with 10% fetal bovine serum (Sigma) and penicillin (100 IU/ml)/streptomycin (Sigma, 100 mg/ml).

Antibodies
The following primary antibodies were used for western blot analysis: mouse anti-actin (MAB1501, Chemicon), mouse anti-p53 (pAb122), mouse anti-MDM2 (2A10), mouse anti-MDMX (Sigma MDMX Clone-82, M0445), mouse anti-GAPDH (ThermoFisher, MA5–15738), rabbit anti-Myc (gift from Yue Xiong), mouse anti-GFP (NeoMarkers, clone AB-2). The following antibody was used for immunofluorescent staining: mouse anti-MDMX (Clone 7A8, gift from Jiandong Chen).

siRNA treatment
Cells were treated with 20 μM of siRNA using the Lipo-lectectRNAiMax reagent (ThermoFisher, catalog #13778150). Cells were analyzed 32–36 h after siRNA transfection. MDMX-targeting siRNA duplexes were purchased from Invitrogen (Stealth RNAi siRNA Duplex, siRNA 1 ID: MSS206594, siRNA 2 ID: MSS206595, siRNA 3 ID: MSS206596).

Western blotting
For western blot analysis, cells were lysed in 0.5% Nonidet P-40 buffer containing protease inhibitor mixture (leupeptin, catalog no. L2884; aprotinin, catalog no. A1155; benzamidine, catalog no. B6506; and trypsin inhibitor, catalog no. T9003; all from Sigma), 1 mM PMSF (Sigma, catalog no. P7626), 1 mM NaVO3 (Fisher Scientific, catalog no. S454–50), and 1 mM DTT (Roche, catalog no. 03117014001) for 30 min. 100-150 μg of protein was separated on a 12.5% SDS-PAGE gel prior to transfer to a nitrocellulose membrane (BioRad). Transfers were assessed by staining the membranes with Ponceau S (Sigma, catalog no. P3504) for 5 min, followed by several brief washes with double-distilled H2O. Membranes were blocked for at least 1 h in phosphate-buffered saline containing 5% nonfat milk and 0.1% Tween 20. Membranes were then incubated with the appropriate primary antibody diluted in blocking buffer for 2 h to overnight. Membranes were washed three times in phosphate-buffered saline containing 0.1% Tween 20 and then incubated with the appropriate HRP-conjugated secondary antibody diluted in blocking buffer for 1 h. Membranes were washed four times in PBS-T and then developed with Supersignal West Pico chemiluminescent substrate or Supersignal West Dura chemiluminescent substrate according to the instructions of the manufacturer (Pierce, catalog no. 34080 and 34,075).

Lentiviral transduction
Lentiviral overexpression constructs were generated using the gateway cloning system to insert MDMX constructs into the pLenti4 puro-Dest vector. Vector sequences were verified by DNA sequencing both before and after gateway insertion. For shRNA treatments, MDMX-targeting or nonspecific shRNAs were inserted into the pLKO.1 vector and verified by DNA sequencing. The following shRNA sequences were used to target MDMX: MDMX shRNA 1: GCAAGAAGTTTAATTC
TCCAA, MDMX shRNA 2: GCAGAATTTCTCAGGAA
ACAAA, MDMX shRNA 3: CCGGATGAGAGAGAACCCATT, MDMX shRNA 4: CTCACGTATTACAG
ACAAA, MDMX shRNA 5: GCGCGAGAGACCAACAGATA. Lentiviral particles were generated by the
UNC Lenti-shRNA Core Facility. For lentiviral transduction, cells were plated at 60% confluence in a 6-well
plate and treated with 25-200 μL of lentiviral supernatant in 1 mL total media containing 8 μg/mL hexadimethrine bromide (polybrene, Sigma catalog #107689). Cells were incubated with lentiviral particles for 48 h prior to lysis for protein analysis.

**Immunoprecipitation**

HEK293 cells were plated at 70% confluence in a 60 mm dish and then transfected with 1 μg of plasmid mixture using the Effectene transfection reagent (Qiagen, catalog #301425). 24 h after transfection, cells were lysed in 0.1% nonidet P-40 buffer containing protease inhibitor, PMSF, NaVO3 and DTT. 100 μg of lysate was used as loading control, while 1 mg of lysate was used for immunoprecipitation (IP). Prior to IP, lysates were pre-cleared using 75-100 μL of CL4B beads. IP was performed using anti-Flag M2 affinity gel (Sigma, catalog #A2220) by rotating lysates with 5 μL Flag beads at 4 °C overnight. Beads were then washed three times with 0.1% nonidet P-40 buffer. Precipitated proteins were then isolated in 1X SDS loading buffer and analyzed via western blot.

**Immunofluorescent staining**

MEF cells were plated at low confluence and treated with a low volume (50 μL) of lentiviral particles for 48 h prior to fixation using 10% formalin solution (Sigma, catalog #HT501128). Cells were permeabilized using 0.2% Triton X-100 diluted in phosphate buffered saline for five minutes at 4 °C. Permeabilized cells were then incubated in 0.5% bovine serum albumin (BSA) solution for at least 30 min before overnight exposure to primary antibody solution. Cells were then treated with AlexaFlour 594-conjugated goat anti-mouse secondary antibody (Jackson ImmunoResearch Laboratories) for 30–45 min. Followed by incubating with 4,6-diamidino-2-phenylindole (DAPI) for 2 min for nuclear counter-staining. After staining, cells were analyzed using an Olympus IX-81 microscope fitted with a SPOT camera and software. Signal brightness and contrast was increased equally for all images using ImageJ software for clear signal visualization.

**Abbreviations**

MDM2: mouse double minute 2; MDMX: mouse double minute 4; MEF: mouse embryonic fibroblast cells; RING: really interesting new gene; NLS: nuclear localization signal; TAD: transcriptional activation domain; HEK293: human embryonic kidney 293 cells

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12860-021-00385-3.

**Additional file 1.**

**Acknowledgements**

The authors would like to thank Andrew Se for his technical assistance during the course of this study.

**Authors’ contributions**

JS, JY, and JH, designed and executed experiments and analyzed data. LT and AJ generated the mouse line and MEF cells that were investigated in this study. JS and YZ conceived the study and wrote the manuscript. AJ provided technical support. All authors read and approved the final manuscript.

**Funding**

Research in this study was funded through the following National Institutes of Health research grants: 5R01CA212407–04, 5T32CA071341–22.

**Availability of data and materials**

All data generated or analysed during this study are included in this published article. Contact the corresponding author regarding availability of reagents and materials used in this study.

**Declarations**

**Conflict of interest**

The authors declare that they have no conflicts of interest with the contents of this article.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
2Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
3Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
4Jiangsu Province Key Laboratory of Immunity and Metabolism and Department of Pathogenic Biology and Immunology, Xuzhou Medical University, Xuzhou 221002, Jiangsu, China.
5Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.

Received: 27 January 2021 Accepted: 20 August 2021
Published online: 22 September 2021

**References**

1. Kruiswijk F, Labuschagne CF, Vosden KH. P53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat Rev Mol Cell Biol. 2015;16(7):393–405. https://doi.org/10.1038/nrm4007.

2. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 1995;378(6553):203–6. https://doi.org/10.1038/378203a0.

3. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 1995;378(6553):206–8. https://doi.org/10.1038/378206a0.

4. Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG, et al. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with Mdm2 to regulate p53. Nat Genet. 2001;29(1):92–5. https://doi.org/10.1038/ng714.
5. Haupt Y, Maya R, Kazaz A, Oren M. MDM2 promotes the rapid degradation of p53. Nature. 1997;387(6630):299–303. https://doi.org/10.1038/37290a0.

6. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997;40(1):25–7. https://doi.org/10.1016/S0014-5793(97)01480-4.

7. Kabbatou M, Jones SN, Vousden KH. Regulation of p53 stability by MDM2. Nature. 1997;387(6630):299–303. https://doi.org/10.1038/37290a0.

8. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69(7):1237–45. https://doi.org/10.1016/0092-8674(92)90464-R.

9. Jackson NW, Berberich SJ. MdmX protects p53 from Mdm2-mediated degradation. Mol Cell Biol. 2000;20(5):1001–7. https://doi.org/10.1128/MCB.2.0.1001-1007.2000.

10. Sabatini P, Mccormick F. MDMX inhibits the p300/CPB-mediated acetylation of p53. DNA Cell Biol. 2002;21(7):519–25. https://doi.org/10.1089/10445400220019077.

11. Tanimura S, Ohtsuka S, Mitsui K, Shirouzu K, Yoshimura A, Ohtsubo M. MDM2 interacts with MDMX through their RING finger domains. FEBS Lett. 1999;447(1):5–9. https://doi.org/10.1016/S0014-5793(99)00254-9.

12. Linke K, Mace PD, Smith CA, George D, Levine AJ. The MDM2 RING domain C-terminus is required for ubiquitination in trans. Cell Death Differ. 2008;15(5):841–8. https://doi.org/10.1038/cdd.2008.39.

13. Nomura K, Klejnot M, Kowalczyk D, Hock AK, Sibbet GJ, Vousden KH, et al. Structural analysis of MDM2/RING prevents degradation from regulation of p53 transcription activity. Nat Struct Mol Biol. 2017;24(7):578–87. https://doi.org/10.1038/nsmb.3414.

14. Kostic M, Matt T, Martinez-Yamout MA, Dyson HJ, Wright PE. Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53. J Mol Biol. 2006;363(2):433–50. https://doi.org/10.1016/j.jmb.2006.08.027.

15. Ohtsubo C, Shiozawa D, Kodama M, Gaiddon C, Nakagama H, Jochemsen AG, et al. Cytoplasmic tethering is involved in synergistic inhibition of p53 by Mdmx and Mdm2. Cancer Sci. 2009;100(7):1291–7. https://doi.org/10.1111/j.1349-7006.2009.01180.x.

16. Donezlova P, Cetkovska K, Vousden KH, Uldrijan S. Mutational analysis of the extreme C terminus of MDMX. EMBO J. 2007;26(1):102–10. https://doi.org/10.1038/sj.emboj.7601465.

17. Linares LK, Hengstermann A, Ciechanover A, Muller S, Scheffner M. HdmX phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J. 2005;24(19):3411–22. https://doi.org/10.1038/sj.emboj.7600812.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.